Article

Early RA Dsease Management May Reduce Risk of Cardiovascular Disease

Inflammation early in the rheumatoid arthritis (RA) disease course is associated with 2 measures of arterial stiffness, increased pulse-wave velocity (PWV) and augmentation index (AIx), after 15 years. Early, active disease management to control inflammation in patients with RA may help reduce the risk of later cardiovascular (CV) disease.

Inflammation early in the rheumatoid arthritis (RA) disease course is associated with 2 measures of arterial stiffness, increased pulse-wave velocity (PWV) and augmentation index (AIx), after 15 years. Early, active disease management to control inflammation in patients with RA may help reduce the risk of later cardiovascular (CV) disease.

Provan and associates followed 238 patients with early RA longitudinally; 108 were available for the 15-year follow-up examination. Comprehensive baseline clinical (eg, C-reactive protein [CRP] level) and radiographic data were collected, and AIx and PWV were recorded at the 15-year follow-up. The association between baseline variables and later increased AIx and PWV were examined in parallel logistic regression procedures, with adjustments for age, sex, and mean arterial pressure.

Elevated baseline CRP level predicted increased AIx and PWV at 15 years in univariate and multivariate models. Current CRP level increased the odds ratio for increased PWV for patients with an elevated baseline CRP level, without contributing independently to the model. Female sex was a significant positive effect modifier of elevated baseline CRP level in the prediction of increased PWV.

The authors noted that the PWV is an established independent predictor of all-cause and CV mortality in populations with and those without pathological conditions.

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
© 2024 MJH Life Sciences

All rights reserved.